Respiratory Syncytial Virus Infection in Older Adults: An Update

Area of Science:

• Virology
• Immunology
• Public Health

Background:

• Respiratory syncytial virus (RSV) is a widespread pathogen causing significant childhood illness and is increasingly recognized as a major threat to older adults.
• The incidence of medically attended RSV infections rises with age, peaking in individuals 70 years and older, posing a substantial public health risk due to aging populations and immunosenescence.
• Current standard care for RSV is supportive, highlighting an unmet need for effective preventive and therapeutic strategies, particularly for high-risk populations.

Purpose of the Study:

• To review current and emerging prevention and treatment strategies for respiratory syncytial virus (RSV) illnesses.
• To provide an in-depth analysis of novel vaccination data for older adults.

Main Methods:

• Literature review focusing on RSV epidemiology, clinical presentations, and current management.
• Detailed examination of recent clinical trial data for newly approved RSV vaccines (Arexvy and Abrysvo).

Main Results:

• RSV infection presents a broad spectrum of illness, from mild to life-threatening respiratory distress, with older adults facing the highest risk of severe outcomes.
• New vaccinations, Arexvy (GSK) and Abrysvo (Pfizer), have become available for older adults, representing a significant advancement in RSV prevention.
• The review synthesizes available data on these novel vaccines, offering insights into their efficacy and potential impact.

Conclusions:

• The aging population and immunosenescence increase the risk of RSV epidemics, necessitating urgent development of preventive measures.
• Novel vaccines for older adults offer a promising strategy to combat severe RSV disease and reduce the burden on healthcare systems.
• Continued research and implementation of preventive strategies are crucial to mitigate the impact of RSV in vulnerable populations.